La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Avecho Biotechnology Dividende

Dividende contrôle des critères 0/6

Avecho Biotechnology does not have a record of paying a dividend.

Informations clés

n/a

Rendement du dividende

n/a

Ratio de distribution

Rendement moyen de l'industrie	2.1%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	n/a
Résultat par action	-AU$0.0011
Prévisions de rendement du dividende à 3 ans	n/a

Mises à jour récentes des dividendes

Pas de mise à jour

Recent updates

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Jan 13

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: Insufficient data to determine if AVE's dividends per share have been stable in the past.

Dividende croissant: Insufficient data to determine if AVE's dividend payments have been increasing.

Rendement des dividendes par rapport au marché

Avecho Biotechnology Rendement des dividendes par rapport au marché

Comment le rendement du dividende de AVE se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (AVE)	n/a
25% du marché (AU)	2.6%
25% du marché (AU)	6.1%
Moyenne du secteur (Pharmaceuticals)	2.1%
Prévisions des analystes dans 3 ans (AVE)	n/a

Dividende notable: Unable to evaluate AVE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividende élevé: Unable to evaluate AVE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Bénéfice distribué aux actionnaires

Couverture des revenus: Insufficient data to calculate AVE's payout ratio to determine if its dividend payments are covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: Unable to calculate sustainability of dividends as AVE has not reported any payouts.

Avecho Biotechnology Dividende

Dividende contrôle des critères 0/6

Informations clés

Mises à jour récentes des dividendes

Recent updates

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.001 loss in FY 2022)

Avecho Biotechnology Limited, Annual General Meeting, May 30, 2024

New major risk - Shareholder dilution

Avecho Biotechnology Limited has completed a Follow-on Equity Offering in the amount of AUD 6.04685 million.

First half 2023 earnings released: AU$0.001 loss per share (vs AU$0 in 1H 2022)

Full year 2022 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in FY 2021)

Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth

Athenex Submits Avecho's Phytonadione to FDA Pre-IND

Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia

Less than half of directors are independent

Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk

First half 2022 earnings released: EPS: AU$0 (vs AU$0.001 loss in 1H 2021)

Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation

Less than half of directors are independent

Avecho Biotechnology Limited Announces Positive Results for Its Phase IIa Study

Avecho Biotechnology Limited Announces Dosing Commencement for CBD Topical Osteoarthritis Study in collaboration with the Lambert Initiative

Full year 2021 earnings: Revenues miss analyst expectations

Avecho Biotechnology Limited Releases Results for Its Australian Phase I PK Study Characterizing the Absorption Profile of Cannabidiol from Avecho's Proprietary CBD Soft-Gel Product

Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans

Avecho Commences Enrolment for Phase I Human Clinical Trial Measuring CBD Absorption

We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely

Non-Independent Non-Executive Director David Segal has left the company

Avecho Biotechnology Limited Completes Pharmaceutical CBD Soft-Gel Product

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth

Full year 2020 earnings released: AU$0.002 loss per share (vs AU$0.001 profit in FY 2019)

Avecho Biotechnology Begins Human Trial on CBD Product

We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate

Avecho Biotechnology Limited Provides TPM Cannabinoid Development Program Update

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés